Dr Juliette Lanskey and the teams at the Universities of Cambridge, Oxford and Cardiff have found a new way to monitor how dementia treatments affect the brain—without invasive procedures. Using Magnetoencephalography (MEG) scans and advanced computer modelling, they tracked how common dementia medication interacts with brain receptors in living patients. This offers a safer, quicker way to test if new drugs reach their targets. This technology could speed up dementia research and therapy development.
Read the full scientific paper in Molecular Psychiatry:Alzheimer’s disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography
Read the accessible summary on PsyPost:New brain scanning method safely tracks how Alzheimer's drugs work in living patients